"I'm losing my patience"
As George Bernard Shaw once said, "Nothing is ever done in this world until men are prepared to kill one another if it is not done." While accidental fatalities, even those caused by preventable mistakes and human errors, are a far cry from murder, Don Berwick, MD, has seen enough death. He's also heard enough rhetoric about ways to improve healthcare quality.
He has recently started borrowing a political maxim: "Some is not a number; soon is not a time." During his opening presentation at IHI's 2003 meeting, he asked attendees which would happen first: Americans get the healthcare system they need and deserve, or the Red Sox win the World Series?
"I bet against Boston," says the avowed member of Red Sox Nation. "My mistake. What I should have done is set a deadline for fixing healthcare."
A man who rarely makes the same mistake twice, he now has a very specific, time-sensitive plan: to save 100,000 lives by 9 a.m., June 14, 2006. It will be accomplished by launching IHI's "100,000 Lives Campaign," which aims to incorporate six changes into 1,600 U.S. hospitals within the next year and a half. The words "some" and "soon" don't appear anywhere in his game plan.
THE BIG SIX The Campaign's six change initiatives are:
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Expands Kerendia’s Use to Treat Common Form of Heart Failure
July 14th 2025Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic kidney disease (CKD) associated with type 2 diabetes. This new approval extends its use to a broader patient population.
Read More
